# Pediatric Hypertension: Measure for Age and Context

Use the correct pediatric reference, confirm persistence, and let severity and organ effects determine the urgency of investigation and treatment.

![Infographic: Pediatric Hypertension: Measure for Age and Context](https://urinenephrology.org/visual-reference/images/pediatric-hypertension.png?v=20261003c)

## Age changes the definition

For children under 13, use age-, sex-, and height-based percentiles with the AAP table’s lower absolute cutoffs. From age 13, stage 1 is 130–139/80–89 and stage 2 is ≥140/90 mmHg. An adult cutoff alone can miss hypertension in a small child.

## Confirm the reading

Use a cuff sized to the arm, supported positioning, quiet rest, and a validated device. Repeat an elevated automated value by auscultation. Persistent diagnosis usually requires auscultatory-confirmed elevation at separate visits; severe symptoms or extreme readings need immediate assessment rather than routine waiting.

## Use ABPM to resolve the phenotype

Pediatric ABPM helps confirm persistent hypertension and distinguish white-coat or masked patterns, especially in CKD or high-risk children. Use pediatric standards and an adequate recording; adult wake/sleep cutoffs cannot simply replace the relevant age/height framework.

## Look for secondary clues

Review kidney/urinary history, birth history, medicines/stimulants, sleep symptoms, family history, and growth. Examine pulses and upper/lower limb pressures when appropriate. Younger age, severe hypertension, abnormal urinalysis, or impaired function increases concern for a secondary renal or vascular cause.

## Decide when lifestyle is insufficient

Symptoms, stage 2 disease without a readily modifiable factor, LV hypertrophy, CKD/diabetes, or persistent hypertension despite lifestyle measures support medication evaluation. Work with the family on food, activity, and sleep without stigma; treatment should not wait indefinitely for weight loss.

## Track organs and function

Recheck BP, growth, adherence, adverse effects, and drug-specific kidney/electrolyte labs. AAP’s usual treatment goal is below the 90th percentile and below 130/80 in adolescents; CKD may require a more specific ambulatory target under pediatric nephrology care.

## Supporting evidence

- [Supporting guideline or source](https://publications.aap.org/pediatrics/article/140/3/e20171904/38358/)

## Source lessons

- [pediatric hypertension](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/pediatric-hypertension.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.